Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Minerva Neuroscie (NERV)

Minerva Neuroscie (NERV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 17,484
  • Shares Outstanding, K 6,993
  • Annual Sales, $ 0 K
  • Annual Income, $ -30,010 K
  • 60-Month Beta 0.22
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade NERV with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -1.20
  • Number of Estimates 1
  • High Estimate -1.20
  • Low Estimate -1.20
  • Prior Year -1.31
  • Growth Rate Est. (year over year) +8.40%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.40 +4.17%
on 03/01/24
3.19 -21.55%
on 02/28/24
-0.30 (-10.71%)
since 02/27/24
3-Month
2.40 +4.17%
on 03/01/24
13.49 -81.47%
on 02/07/24
-4.00 (-61.54%)
since 12/27/23
52-Week
1.58 +58.23%
on 04/03/23
13.49 -81.47%
on 02/07/24
+0.86 (+52.44%)
since 03/27/23

Most Recent Stories

More News
Minerva Neurosciences: Q4 Earnings Snapshot

Minerva Neurosciences: Q4 Earnings Snapshot

NERV : 2.50 (-2.72%)
Minerva Neurosciences: Q3 Earnings Snapshot

Minerva Neurosciences: Q3 Earnings Snapshot

NERV : 2.50 (-2.72%)
Minerva Neurosciences: Q2 Earnings Snapshot

Minerva Neurosciences: Q2 Earnings Snapshot

NERV : 2.50 (-2.72%)
Bump up Your Long Term Portfolio Performance With Low Beta Stocks

In this article, discover how low beta stocks can shimmer in your portfolio!

MSFT : 421.09 (-0.08%)
NERV : 2.50 (-2.72%)
STIX : 0.9600 (+7.24%)
SERA : 9.46 (-0.42%)
TCRX : 8.30 (+3.88%)
NVCT : 8.34 (+1.09%)
Minerva Neurosciences: Q1 Earnings Snapshot

Minerva Neurosciences: Q1 Earnings Snapshot

NERV : 2.50 (-2.72%)
Minerva Neurosciences: Q4 Earnings Snapshot

Minerva Neurosciences: Q4 Earnings Snapshot

NERV : 2.50 (-2.72%)
Minerva (NERV) Down; FDA Denies Review Schizophrenia Drug NDA

Minerva (NERV) confirmed that the FDA's refuse-to-file letter on its regulatory filing, seeking approval for roluperidone, to treat symptoms of schizophrenia remains in effect.

CANF : 2.26 (+3.67%)
NERV : 2.50 (-2.72%)
AMLX : 2.86 (-0.69%)
ACER : 0.6601 (-17.95%)
Greater Prevalence of Anxiety & Depressive Disorders Driving Demand for New Anti-Anxiety Drug Candidates

EQNX::TICKER_START (NASDAQ:SAGE),NASDAQ:NERV),(NASDAQ:ATAI),(NYSE:CYBN),(TSXV:MRVL),(NEO:CYBN), EQNX::TICKER_END

CYBN.NE : 0.5700 (unch)
MRVL.VN : 0.150 (-6.25%)
SAGE : 19.04 (+2.26%)
NERV : 2.50 (-2.72%)
ATAI : 1.8100 (+1.12%)
CYBN : 0.4253 (-1.09%)
Greater Prevalence of Anxiety & Depressive Disorders Driving Demand for New Anti-Anxiety Drug Candidates

/PRNewswire/ -- FinancialNewsMedia.com News Commentary - Anti-anxiety drugs are medications that are used to treat anxiety disorders that are mainly used to...

MRVL.VN : 0.150 (-6.25%)
SAGE : 19.04 (+2.26%)
NERV : 2.50 (-2.72%)
ATAI : 1.8100 (+1.12%)
CYBN : 0.4253 (-1.09%)
Minerva Neurosciences: Q3 Earnings Snapshot

Minerva Neurosciences: Q3 Earnings Snapshot

NERV : 2.50 (-2.72%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. The Company's pipeline will initially target the treatment of schizophrenia, major depressive...

See More

Key Turning Points

3rd Resistance Point 2.79
2nd Resistance Point 2.71
1st Resistance Point 2.60
Last Price 2.50
1st Support Level 2.41
2nd Support Level 2.33
3rd Support Level 2.22

See More

52-Week High 13.49
Fibonacci 61.8% 8.94
Fibonacci 50% 7.53
Fibonacci 38.2% 6.13
Last Price 2.50
52-Week Low 1.58

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar